These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Holst JJ Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141 [TBL] [Abstract][Full Text] [Related]
4. The physiology of incretin hormones and the basis for DPP-4 inhibitors. McKennon SA; Campbell RK Diabetes Educ; 2007; 33(1):55-6, 60-2, 65-6. PubMed ID: 17272793 [TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Green BD; Flatt PR; Bailey CJ Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910 [TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Mest HJ; Mentlein R Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466 [TBL] [Abstract][Full Text] [Related]
7. What are incretins, and how will they influence the management of type 2 diabetes? Blonde L; Rosenstock J; Triplitt C J Manag Care Pharm; 2006 Sep; 12(7 Suppl A):S2-12; quiz S14-6. PubMed ID: 16981805 [TBL] [Abstract][Full Text] [Related]
8. Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors. Siminerio L Diabetes Educ; 2007; 33 Suppl 5():111S-3S. PubMed ID: 17548898 [No Abstract] [Full Text] [Related]
9. Sitagliptin: a viewpoint by Mark S. Kipnes. Kipnes MS Drugs; 2007; 67(4):598-9. PubMed ID: 17352517 [No Abstract] [Full Text] [Related]
11. Finding new treatments for diabetes--how many, how fast... how good? Nathan DM N Engl J Med; 2007 Feb; 356(5):437-40. PubMed ID: 17267901 [No Abstract] [Full Text] [Related]
12. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Nauck MA; El-Ouaghlidi A Diabetologia; 2005 Apr; 48(4):608-11. PubMed ID: 15761719 [No Abstract] [Full Text] [Related]
14. New drugs for the treatment of type 2 diabetes. Chowdhury TA; Hossain B Br J Hosp Med (Lond); 2007 Apr; 68(4):178-83. PubMed ID: 17465090 [TBL] [Abstract][Full Text] [Related]
15. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. Mari A; Sallas WM; He YL; Watson C; Ligueros-Saylan M; Dunning BE; Deacon CF; Holst JJ; Foley JE J Clin Endocrinol Metab; 2005 Aug; 90(8):4888-94. PubMed ID: 15886245 [TBL] [Abstract][Full Text] [Related]
16. Drugs on the horizon for diabesity. Bailey CJ Curr Diab Rep; 2005 Oct; 5(5):353-9. PubMed ID: 16188170 [TBL] [Abstract][Full Text] [Related]
17. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. Winkler G Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951 [TBL] [Abstract][Full Text] [Related]
18. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ; Nauck MA Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Raz I; Hanefeld M; Xu L; Caria C; Williams-Herman D; Khatami H; Diabetologia; 2006 Nov; 49(11):2564-71. PubMed ID: 17001471 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE; Lau J; Pittas AG JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]